COMMUNIQUÉS West-GlobeNewswire

Levicept Announces FDA Acceptance of IND Application for LEVI-04, a Potentially Disease-Modifying Treatment for Osteoarthritis
20/01/2026
SANDWICH, United Kingdom, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the US Food [...]
smartbax in-licenses lead antibacterial compound targeting Gram-negative infections from Aicuris
20/01/2026
Munich, Germany, Jan. 20, 2026 (GLOBE NEWSWIRE) -- smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the in-licensing of a new compound class from [...]
Nicox annonce sa participation à des congrès au premier semestre 2026 et la présentation prochaine de données scientifiques
20/01/2026
Communiqué de presse Nicox annonce sa participation à des congrès au premier semestre 2026 et la présentation prochaine de données scientifiques 20 janvier 2026 – publication à 7H30 Sophia Antipolis, France Nicox SA ( [...]
Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations
20/01/2026
Press Release Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations January 20, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124 [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
20/01/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 20 January 2026 at 08.30 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Nxera Pharma Establishes Metabolic Advisory Council to Advance Next-Generation Therapies for Obesity and Metabolic Disorders
20/01/2026
Council brings together leading global scientific and clinical experts in metabolic diseases to guide development of Nxera’s expanding proprietary pipeline Tokyo, Japan and Cambridge, UK, 20 January 2026 – Nxera Pharma [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 décembre 2025
19/01/2026
DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l’article 222-12-5 du règlement général de l’AMF, les [...]
Virbac: solide croissance en 2025 avec un chiffre d'affaires annuel en hausse de +7,9 % à pcc3, forte dynamique dans les catégories et pays clés
19/01/2026
Le chiffre d'affaires annuel 2025 atteint 1 465 M€ +7,9 % à taux de change et périmètre constants (pcc) comparé à 2024 +4,8 % à taux réels, impactés par des effets de change très défavorables, notamment en Amérique [...]
Virbac: solid 2025 dynamic with annual revenue up +7.9% at CERS3; with strong momentum in key categories and countries
19/01/2026
Full-year 2025 revenue reached €1,465m : +7.9% at constant exchange rate and scope (CERS) vs 2024 +4.8% at actual rates impacted by significant currency headwinds, particularly in Latin America, IMEA and the Pacific. [...]
GUERBET : Bilan semestriel du contrat de liquidité
19/01/2026
Bilan semestriel du contrat de liquidité Villepinte, le 19 janvier 2026 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, présente aujourd’hui le bilan [...]
Metabo Drops 2026 [Latest Update]: Is It Legit? Liquid Delivery Science, Ingredient Research, and Informed Consumer Analysis
19/01/2026
Consumer verification searches for Metabo Drops have intensified as "Is It Legit?" queries and ingredient transparency questions reshape how buyers evaluate liquid metabolism drops — this 2026 analysis examines safety [...]
SAFE ORTHOPAEDICS FRANCHIT UNE ETAPE STRATEGIQUE : SIGNATURE DE SON PREMIER CONTRAT DE DISTRIBUTION AU BRESIL
19/01/2026
SAFE ORTHOPAEDICS FRANCHIT UNE ETAPE STRATEGIQUE : SIGNATURE DE SON PREMIER CONTRAT DE DISTRIBUTION AU BRESIL Fleurieux-sur-l’Arbresle – France – 19 janvier 2026 – 18h - Safe (FR001400ZU25 – ALSAF), annonce que sa [...]
Valneva fait un point sur son vaccin contre le chikungunya IXCHIQ®
19/01/2026
La Société retire volontairement ses demandes d’autorisation de mise sur le marché (BLA) et d’essais cliniques (IND) aux États-Unis Et continue d’évaluer le potentiel mondial du produit en fonction des besoins médicaux [...]
Valneva Provides Update on Chikungunya Vaccine IXCHIQ®
19/01/2026
Company voluntarily withdraws IXCHIQ BLA and IND in the U.S. Continuing review of global product opportunity according to medical need and commercial attractiveness Saint Herblain (France), January 19, 2026 – Valneva SE [...]
BVI Appoints Jim Hollingshead as President & Chief Executive Officer
19/01/2026
WALTHAM, Mass., Jan. 19, 2026 (GLOBE NEWSWIRE) -- BVI, a global leader in the ophthalmic device market, announced today the appointment of Jim Hollingshead as President & Chief Executive Officer. Hollingshead [...]
Immuron Reports Continued Sales Growth
19/01/2026
Sales Highlights (unaudited): Global H1 sales AUD$4.2 million up 5% on prior comparative period (pcp) Q2 sales AUD$2.2 million up 11% on prior quarter Australia H1 sales AUD$3.3 million up 13% on prior comparative [...]
CUKTECH Launches 30 Ultra Charging Station in Malaysia, Redefining the Desktop Charging Experience
19/01/2026
KUALA LUMPUR, Malaysia, Jan. 19, 2026 (GLOBE NEWSWIRE) -- CUKTECH has officially announced the launch of its flagship product, the CUKTECH 30 Ultra Charging Station , arriving in Malaysia at 8:00 PM on January 16, 2026 [...]
MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO
19/01/2026
TORONTO, Jan. 19, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
19/01/2026
COPENHAGEN, Denmark, January 19, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount [...]

Pages